Skip to content

The effect of benzoic acid intake on kidney transplant recipients

The Benzoic Acid and Nutritional and Clinical Health in Kidney Transplantation (BANCH) trial - The Benzoic Acid and Nutritional and Clinical Health in Kidney Transplantation (BANCH) trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON61255
Enrollment
27
Registered
2026-01-02
Start date
2026-08-01
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney transplant recipients with reduced kidney function People with a kidney transplant whose kidney function is reduced

Interventions

A 4-week benzoic acid–reduced diet, based on established benzoate-free dietary protocols described in the literature, optimized with the nutrition team of the UMCG to maintain stable vitamin C intake.

Sponsors

Universitair Medisch Centrum Groningen
Lead Sponsor

Eligibility

Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: In order to be eligible to participate in this study, a participant must meet all of the following criteria:Patients older than 18 years=1 year after kidney transplantationeGFR =20 and =60 mL/min/1.73m²The participant consumes products rich in benzoic acid (such as soft drinks, processed foods, and flavoured products) at least 3 times per week.

Exclusion criteria

Exclusion criteria: A potential participant who meets any of the following criteria will be excluded from participation in this study:Patients who are unable to comprehend the instructions of the nutrition team, the questionnaires, and testsUnable or unwilling to adhere to the dietary recommendations of the study protocol Patients following a specific dietary pattern (vegetarian, vegan, paleo)Urinary protein excretion >1gr/24 hoursLife expectancy =1 year

Design outcomes

Primary

MeasureTime frame
The primary outcome measure of the trial is the urinary trans,trans-muconic acid (ttMA) excretion, a biomarker of benzene exposure, measured three times during each 4-week intervention or control period.

Secondary

MeasureTime frame
 Secondary endpoints include change in plasma vitamin C concentration, quality of life, plasma creatinine concentration; haemoglobin concentration; total white blood cell count; C-reactive proteine; plasma malondialdehyde concentration; and gut microbiome composition. Adherence will be evaluated using a 24-hour dietary recall with calculation of benzoate and vitamin C intake

Countries

Netherlands

Contacts

Public ContactM Yepes Calderon

Universitair Medisch Centrum Groningen

m.yepes.calderon@umcg.nl0625648254

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Jun 29, 2026